Title: Levetiracetam (Keppra) for Status Epileptics
题目：左乙拉西坦在癫痫持续状态中的应用
Author 作者: Ellen Lemkin
 
Although Keppra has been used more frequently in clinical practice, there is little evidence for its use in status epilepticus.
虽然左乙拉西坦在临床实践中已被广泛应用，但它在癫痫持续状态中应用的资料有限。
It has a wide spectrum of action and few drug interactions.
它的作用广泛并很少有药物之间的反应。
Initially, case series appeared to be highly successful in terminating seizures as an add-on agent.
首先，病例报告显示它做为一个终止癫痫的辅药的效果是非常理想的。
A review of 2 prospective studies found efficacies of 44% as an add- on agent, and 75% as a primary agent. The studies had markedly different populations.
一个对两个前瞻性研究文献的综述发现，左乙拉西坦做为辅助药的效果为44％，做为一线药的效果为75％。它们在研究人群方面有明显的差别。
In a retrospective study, the treatment failure rates were 3X higher than that of intravenous valproic acid as an add-on agent in terminating status epilepticus.
在一个回顾性报告中，它做为终止癫痫持续状态辅助药的治疗失败率是丙戊酸的3倍。
Therefore, although it is used frequently, the evidence for use is limited and inconclusive in terminating status epilepticus.
因此，虽然它用的广泛，但支持它在治疗癫痫持续状态中应用的证据是有限和不明确的。

References 参考文献： 
Trinka E. What is the evidence to use new intravenous AED in status epilepticus? Epilepsia 2011 52(Suppl 8):35-8.
Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: A systematic review. Seizure 2012. 21:233-6.